Académique Documents
Professionnel Documents
Culture Documents
34 y/o C/C: Body Malaise & Vomiting Dx: Hyperemesis Grvidarum INDICATIONS AND CONTRAINDI GENERIC NAME DOSAGE CATIONS
Ranitidine Hydrochloride
BRAND NAME Zantac*, Zantac-C, Zantac 75, Zantac 300, Taladine,FusePaq Deprizine DRUG CLASSIFICATION Zantac 150, Zantac 150 Efferdose,
SIDE EFFECTS Active duodenal and constipation, gastric ulcer Contraindicate diarrhea, Adults: 150 mg P.O. b.i.d. d in patients fatigue, or 300 mg daily at bedtime. hypersensitive to headache, Or, 50 mg I.V. or I.M. every drug and those insomnia, 6 to 8 hours. Maximum with acute muscle pain, daily I.V. dose, 400 mg. Or, porphyria. nausea, and 150 mg by continuous infusion at 6.25 mg/hour vomiting Use
over 24 hours.
ADVERSE EFFECTS
CNS vertigo EENT blurred vision Hepatic jaundice Other
Gender: Female Date of Birth: February 4, 1960 Date of Admission: March 24, 2012 Ward/Room: OB Ward/306 SN: Jeg Emmanuel Rommel B. Israel NURSING PATIENT TEACHING CONSIDERATIONS
Assess patient for abdominal pain. Note presence of blood in emesis, stool, or gastric aspirate. Drug may be added to total parenteral nutrition solutions. Look alike-sound alike: Don't confuse ranitidine with rimantadine; don't confuse Zantac with Xanax or Zyrtec. Instruct patient on proper use of OTC preparation, as indicated. Remind patient to take once-daily prescription drug at bedtime for best results. Instruct patient to take without regard to meals because absorption isn't affected by food. Tell patient taking 150mg EFFERdose to dissolve drug in 6 to 8 ounces of water before taking. Tell parent to dissolve 25-mg EFFERdose tablet in at least 5 ml of water and give with a dosing cup, medicine dropper, or oral syringe. Urge patient to avoid cigarette smoking because this may increase gastric acid secretion and worsen disease. Advise patient to report abdominal pain and blood in stool or emesis. Warn patients with phenylketonuria that EFFERdose granules and tablets contain aspartame.
Antiulcerative
- Competitively inhibits action of histamine on the H at receptor sites of parietal cells, decreasing gastric acid secretion.
2
gastric ulcers only, 2 to 4 mg/kg P.O. b.i.d., up to 300 mg/day. Maintenance therapy for duodenal or gastric ulcer Adults: 150 mg P.O. at bedtime.
cautiously in patients with hepatic dysfunction. Adjust dosage in patients with impaired renal function.
anaphylaxis angioedema
AVAILABLE FORMS
Granules (effervescent): 150 mg Infusion: 1 mg/ml in 50-ml containers Injection: 25 mg/ml Syrup: 15 mg/ml* Tablets: 75 mg, 150 mg, 300 mg Tablets (effervescent): 25 mg, 150 mg
ROUTE P.O. & I.V
PREGNANCY RISK CATEGORY B
symptomatic or gastric acid output is greater than 10 mEq/hour, increase dose in increments of 0.5 mg/kg/hour and recheck gastric acid output. Doses up to 2.5 mg/kg/hour and infusion rates up to 220 mg/hour have been used. Gastroesophageal reflux disease Adults: 150 mg P.O. b.i.d.
P.O. daily given as two divided doses. Erosive esophagitis Adults: 150 mg P.O. q.i.d. Maintenance dosage is 150 mg P.O. b.i.d.
75 P.O. as symptoms occur, up to 150 mg daily, not to exceed 2 weeks of continuous treatment.
Adjust-a-dose: For patients with creatinine clearance below 50 ml/minute, 150 mg P.O.